ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
ArriVent BioPharma announced that initial Phase 1 safety and efficacy data for CDH17-targeted ADC ARR-217 (MRG007) in gastrointestinal cancers will be presented at the ESMO Congress 2026 in Madrid. The first-in-human data was selected for a late-breaking rapid oral presentation (abstract LBA34) on October 25, and the company will host a virtual webinar on October 26 at 8 am ET to discuss the data.
Key figures
- Drug Name
- ARR-217 (MRG007)
- Phase Of Trial
- Phase 1
- Webinar date
- October 26, 2026 at 8 am ET
- Abstract number
- LBA34
- Presentation date
- October 25, 2026
- Trial registration
- NCT07066657
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.